B.C.G. was effective and treatment was successful even if given several days after tumour challenge. B.C.G. administered intravenously or subcutaneously was without influence on pleural tumour growth. Similarly, peritoneal growth of these sarcomata was suppressed only by the intraperitoneal injections of B.C.G. organisms.
In contrast, pleural or peritoneal growths from cells of other rat tumours, which lacked significant immunogenicity, were not controlled by this type of B.C.G. treatment. Nevertheless, these studies indicate the potential of B.C.G. Chemically induced and spontaneously arising rat tumours express embryonic antigens, which are also demonstrable on embryo cells taken between 14 and 16 days of gestation. The expression of tumour associated embryonic antigens may be a common feature of malignant transformation since these antigens are present on tumours which lack demonstrable levels of tumour specific rejection antigens. Also, unlike the tumour rejection antigens associated with chemically induced tumours, they show cross-reactivity, especially between tumours of the same histological type. This suggests that the tumour associated embryonic antigens, which differ from other embryonic products such as cx-foetoprotein in being immunogenic in the autochthonous host, may be appropriate markers for immunodiagnostic assays. This is further emphasized by studies to be discussed, showing that homogeneous preparations of soluble embryonic antigen can be isolated readily from tumour cytoplasmic fractions, indicating the possibility of utilizing defined reagents in immunoassays for monitoring circulating tumour antigen. Hepatoma D23 antigen has been monitored in the serum of tumour bearing rats using an antibody inhibition assay based upon membrane immunofluorescence methods for detecting antibody in tumour immune sera. Simultaneously, levels of tumour specific antibody in sera of tumour bearing rats were analysed by their direct membrane immunofluorescence staining with hepatoma D23 cells. Applying these techniques, it has been established that during the early stages of subcutaneous growth of hepatoma D23 in syngeneic rats there is significant shedding of tumour specific antigen into the circulation. This is then depressed after a period of between 10 and 14 days tumour growth, at which time circulating tumour specific immune complexes are detectable. Finally, antibody can be detected. These observations are relevant to current views that cell mediated immunity to tumour cells can be blocked by interaction of antibody or immune complexes with tumour cells or by antigen inhibition of effector cells. Furthermore, these model studies indicate the importance of designing immunochemical assays for diagnostic and prognostic purposes during tumour therapy. 
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